🦠 Clostridioides difficile Infection (CDI) Treatment
This tool gives the Clostridioides difficile infection regimen by episode and severity, covering initial, recurrent, and fulminant disease.
Clinical takeaway
Metronidazole is no longer a first-line agent and is reserved for non-severe disease only when a preferred drug is unavailable. (original synthesis · not guideline verbatim)
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Use to choose fidaxomicin or vancomycin for initial/recurrent CDI, taper-pulse or FMT for multiple recurrences, and high-dose vancomycin + IV metronidazole for fulminant disease.
How it works
Initial (non-severe/severe) → fidaxomicin or oral vancomycin × 10 days. First recurrence → fidaxomicin or vancomycin taper-pulse. Multiple recurrences → taper-pulse/rifaximin/FMT. Fulminant → high-dose vancomycin + IV metronidazole + surgery.
Key points
- Metronidazole is no longer a first-line agent and is reserved for non-severe disease only when a preferred drug is unavailable. (original synthesis · not guideline verbatim)
- A test of cure is not performed, since asymptomatic carriage can persist.
- Bezlotoxumab may be added to reduce recurrence in high-risk patients.
References
- Johnson S, et al. IDSA/SHEA 2021 Focused Update Guidelines on Management of CDI in Adults. Clin Infect Dis 2021.
- Kelly CR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of CDI. Am J Gastroenterol 2021.
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Episode | Initial |
|---|---|
| Severity | Non-severe (WBC ≤ 15,000 and creatinine ≤ 1.5 mg/dL) |
→RegimenFidaxomicin or vancomycin (oral)
- Treatment：Initial (non-severe or severe): fidaxomicin 200 mg bid × 10 days (preferred, fewer recurrences) or vancomycin 125 mg qid × 10 days PO; both superior to metronidazole
- Severity：Non-severe (WBC ≤ 15,000 and creatinine ≤ 1.5 mg/dL)
- General：Stop inciting antibiotics where possible, avoid antimotility agents; metronidazole only if a first-line drug is unavailable and disease is non-severe; do not perform a test of cure
| Episode | Multiple recurrences |
|---|---|
| Severity | Fulminant (+ hypotension/shock/ileus/toxic megacolon) |
→RegimenFulminant: high-dose vancomycin + IV metronidazole
- Fulminant treatment：Vancomycin 500 mg qid PO/NG + IV metronidazole (add vancomycin retention enema if ileus is present); fidaxomicin not studied in fulminant disease
- Surgery：Toxic megacolon/perforation/shock or no improvement after 48–72 h of drug therapy: surgical consult for subtotal colectomy; fecal microbiota transplant (FMT) may be considered if refractory
- Support：Fluid resuscitation, correct electrolytes, avoid antimotility agents; stop the inciting antibiotics and proton-pump inhibitors where possible
Frequently asked questions
- What is Clostridioides difficile Infection (CDI) Treatment?
- This tool gives the Clostridioides difficile infection regimen by episode and severity, covering initial, recurrent, and fulminant disease.
- How is Clostridioides difficile Infection (CDI) Treatment calculated? What is the core formula?
- Initial (non-severe/severe) → fidaxomicin or oral vancomycin × 10 days. First recurrence → fidaxomicin or vancomycin taper-pulse. Multiple recurrences → taper-pulse/rifaximin/FMT. Fulminant → high-dose vancomycin + IV metronidazole + surgery.
- When is Clostridioides difficile Infection (CDI) Treatment used?
- Use to choose fidaxomicin or vancomycin for initial/recurrent CDI, taper-pulse or FMT for multiple recurrences, and high-dose vancomycin + IV metronidazole for fulminant disease.
- What are the key clinical points for Clostridioides difficile Infection (CDI) Treatment?
- Metronidazole is no longer a first-line agent and is reserved for non-severe disease only when a preferred drug is unavailable. (original synthesis · not guideline verbatim) A test of cure is not performed, since asymptomatic carriage can persist. Bezlotoxumab may be added to reduce recurrence in high-risk patients.
- What are the limits and cautions when using Clostridioides difficile Infection (CDI) Treatment?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Clostridioides difficile Infection (CDI) Treatment calculated in practice? Can you show a worked example?
- Inputs: Episode Initial, Severity Non-severe (WBC ≤ 15,000 and creatinine ≤ 1.5 mg/dL) → Result: Regimen Fidaxomicin or vancomycin (oral)（Treatment: Initial (non-severe or severe): fidaxomicin 200 mg bid × 10 days (preferred, fewer recurrences) or vancomycin 125 mg qid × 10 days PO; both superior to metronidazole, Severity: Non-severe (WBC ≤ 15,000 and creatinine ≤ 1.5 mg/dL), General: Stop inciting antibiotics where possible, avoid antimotility agents; metronidazole only if a first-line drug is unavailable and disease is non-severe; do not perform a test of cure） Inputs: Episode Multiple recurrences, Severity Fulminant (+ hypotension/shock/ileus/toxic megacolon) → Result: Regimen Fulminant: high-dose vancomycin + IV metronidazole（Fulminant treatment: Vancomycin 500 mg qid PO/NG + IV metronidazole (add vancomycin retention enema if ileus is present); fidaxomicin not studied in fulminant disease, Surgery: Toxic megacolon/perforation/shock or no improvement after 48–72 h of drug therapy: surgical consult for subtotal colectomy; fecal microbiota transplant (FMT) may be considered if refractory, Support: Fluid resuscitation, correct electrolytes, avoid antimotility agents; stop the inciting antibiotics and proton-pump inhibitors where possible）